Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Drops By 43.7%

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant decline in short interest in August. As of August 31st, there was short interest totaling 178,126 shares, a decline of 43.7% from the August 15th total of 316,392 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily volume of 691,114 shares, the days-to-cover ratio is presently 0.3 days.

Moleculin Biotech Trading Down 1.5%

Shares of NASDAQ:MBRX traded down $0.01 on Wednesday, hitting $0.74. The company had a trading volume of 265,097 shares, compared to its average volume of 640,854. Moleculin Biotech has a 52-week low of $0.16 and a 52-week high of $15.75. The business has a 50 day moving average of $1.07 and a 200 day moving average of $1.97. The company has a market cap of $14.42 million, a PE ratio of -0.10 and a beta of 1.92.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. As a group, equities analysts predict that Moleculin Biotech will post -2.37 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MBRX shares. HC Wainwright dropped their price target on Moleculin Biotech to $3.00 and set a “buy” rating for the company in a research report on Friday, August 28th. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.